Indication
RAS-mutated
1 clinical trial
1 product
Clinical trial
XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS/pMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.Status: Recruiting, Estimated PCD: 2025-07-01